Earlier results had 27.1% on the combo reaching full skin clearance and 10% weight loss at 36 weeks, versus 5.8% on Taltz alone, Lilly said.
Recap by typeshit. Full story at pharmaphorum.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A short Philstar Life item on PIONEER 8, a trial of oral semaglutide. The material gives only the title, so tap through for the details.
Retatrutide is still in clinical trials, but PharmaVoice reports Lilly is already going after a network of illicit sellers offering it online.
Tirzepatide alone reached 14.8% in the same trial. The catch: up to 27% of people on the combination quit over side effects, per the Motley Fool writeup.
Loading…